Wednesday, December 19, 2012

Video: Are Pats still in good shape?

Sorry, Readability was unable to parse this page for content.

Source: http://nbcsports.msnbc.com/id/21134540/vp/50227662#50227662

us open tennis us open tennis aaliyah Empire State Building shooting Republican National Convention Karlie Redd guild wars 2

Another Progress exec leaves Duke Energy

Duke Energy Corp. on Monday said another top executive from merger partner Progress Energy, Jeff Lyash, plans to leave the company at the end of the year.

Lyash was Duke's executive vice president of energy supply. A Duke (NYSE: DUK) spokesman said he won't be replaced; his duties will be divided between Keith Trent, a top executive for regulated utilities, and Dhiaa Jamil, the company's chief nuclear officer.

Charlotte-based Duke also said it's bringing in Julie Janson from its Midwestern operations to replace Marc Manly as the company's chief legal officer. Duke agreed to move Manly out of that position as part of a settlement to end the North Carolina Utilities Commission's five-month investigation into the company's decision to push out CEO Bill Johnson just hours after he stepped into the job.

The company also tweaked the responsibilities of several other top execs, as described here.

Duke's top ranks have had unusually high turnover since the moment Johnson left. Three of the top-level executives that followed Johnson from Raleigh-based Progress followed him right back out of Duke within days. One of those, John McArthur, has been re-hired by Duke on a temporary basis as part of the settlement.

Chris Bagley covers the legal-services industry, transportation and utilities. Follow him on Twitter @TriBizLaw

Source: http://feeds.bizjournals.com/~r/bizj_triangle/~3/e--tP8risPI/another-progress-exec-leaves-duke.html

NASA grenada grenada Sikh andy reid Sanya Richards Ross decathlon

Tuesday, December 18, 2012

Dummy 'grandpa' thieves don?t fool Rome police




2?C

?

Partly cloudy

Vancouver
  • Detailed Forecast

?

?

  • Search
  • Search

?

  • Subscribe
  • Subscriber??Services
  • ePaper
  • canada.com network

    Newspapers

    ?

    ?

    • National Post
    • Victoria Times Colonist
    • The Province (Vancouver)
    • Vancouver Sun
    • Edmonton Journal
    • Calgary Herald
    • Regina Leader-Post
    • Saskatoon StarPhoenix

    ?

    ?

    ?

    • Windsor Star
    • Ottawa Citizen
    • The Gazette (Montreal)
    • DOSE
    • Postmedia Community Publishing
    • Nanaimo Daily News

    ?

?

?

Source: http://feeds.canada.com/~r/canwest/F228/~3/EX97EV5x2jw/story.html

florida lotto dancing with the stars sean taylor Lisa Robin Kelly Nexus 4 Girl Meets World Jason Babin

Monday, December 17, 2012

Wave of bombings kills 25 across Iraq

BAGHDAD (AP) ? A wave of bombings across Iraq on Monday hit a number of targets, including residents of ethnically disputed areas, killing 25 people and wounding dozens.

The attacks deepen fears that militants are seeking to reignite ethnic and sectarian violence in the country, where tensions remain high over areas contested between Iraq's central government and the Kurdish minority. Also, deadly violence continues between the two dominant ethnic communities ? Sunni and Shiite Muslims.

The deadliest of Monday's attacks took place in al-Mouafaqiyah, a village inhabited by families from the Shabak ethnic group. Seven people were killed and 11 were wounded in the bombing, according to police officials.

The village lies near the city of Mosul, 360 kilometers (225 miles) northwest of Baghdad, and is claimed by Arabs, Turkomen and Kurds. The Shabak have their own distinct language and religious beliefs.

Elsewhere in the north, two car bombs went off in a majority Turkomen neighborhood in the city of Tuz Khormato, killing five people and wounding 26, said Mohammed al-Asi, a spokesman for Salahuddin provincial council.

Like the area near the other attack, Tuz Khormato, about 210 kilometers (130 miles) north of Baghdad, has a mix of Arabs, Kurds and Turkomen competing for control of the city.

Tuz Khormato borders the autonomous Kurdish region. Last month, it was the scene of a shootout between Kurdish guards and Iraqi police that killed one civilian. The Iraqi military and Kurdish fighters responded by moving additional troops into disputed areas, raising the specter of further clashes.

Also Monday, police said a roadside bomb hit a bus carrying Lebanese Shiite pilgrims near Samarra, killing one Lebanese national and the Iraqi driver and wounding eight others, including five Lebanese. Also, a car bomb went off on a bus carrying Iranian pilgrims heading to Samarra, killing two, including an Iranian national.

Another car bomb went off in a commercial area in downtown Baghdad in the afternoon, killing three people and wounding 10, police and health officials said.

Shortly after sunset, a car bomb exploded near an open-air car market in northeastern Baghdad, killing six people and wounding 30 others, said police.

Medics in nearby hospitals confirmed the casualties. All officials spoke on condition of anonymity because they were not authorized to speak to reporters.

On Sunday, a series of attacks targeting two other cities in disputed northern areas left at least eight dead and dozens wounded.

It was unclear who was behind the latest violence, though Sunni Arab insurgents frequently use coordinated bomb attacks to try to undermine the Shiite-led government's authority.

Source: http://news.yahoo.com/wave-bombings-kills-25-across-iraq-152851798.html

academy awards 2012 albert nobbs a star is born oscar nominees oscar nominations 2012 kombucha tea separation of church and state

Saturday, December 15, 2012

What mechanism generates our fingers and toes? Genetic studies confirm a mathematical model

Dec. 14, 2012 ? Researchers have identified the mechanism responsible for generating our fingers and toes, and revealed the importance of gene regulation in the transition of fins to limbs during evolution.

Dr. Marie Kmita and her research team at the IRCM contributed to a multidisciplinary research project. Their scientific breakthrough is published today in the journal Science.

By combining genetic studies with mathematical modeling, the scientists provided experimental evidence supporting a theoretical model for pattern formation known as the Turing mechanism. In 1952, mathematician Alan Turing proposed mathematical equations for pattern formation, which describes how two uniformly-distributed substances, an activator and a repressor, trigger the formation of complex shapes and structures from initially-equivalent cells.

"The Turing model for pattern formation has long remained under debate, mostly due to the lack of experimental data supporting it," explains Dr. Rushikesh Sheth, postdoctoral fellow in Dr. Kmita's laboratory and co-first author of the study. "By studying the role of Hox genes during limb development, we were able to show, for the first time, that the patterning process that generates our fingers and toes relies on a Turing-like mechanism."

In humans, as in other mammals, the embryo's development is controlled, in part, by "architect" genes known as Hox genes. These genes are essential to the proper positioning of the body's architecture, and define the nature and function of cells that form organs and skeletal elements.

"Our genetic study suggested that Hox genes act as modulators of a Turing-like mechanism, which was further supported by mathematical tests performed by our collaborators, Dr. James Sharpe and his team," adds Dr. Marie Kmita, Director of the Genetics and Development research unit at the IRCM. "Moreover, we showed that drastically reducing the dose of Hox genes in mice transforms fingers into structures reminiscent of the extremities of fish fins. These findings further support the key role of Hox genes in the transition of fins to limbs during evolution, one of the most important anatomical innovations associated with the transition from aquatic to terrestrial life."

The study published in Science was a collaborative project between the teams supervised by Drs. Marie Kmita (IRCM), James Sharpe (CRG Barcelona, Spain) and Maria A. Ros (University of Cantabria, Spain). The research conducted at the IRCM was funded by the Canadian Institutes of Health Research and the Canada Research Chairs Program. The article's second first author Is Luciano Marcon from the European Molecular Biology Laboratory (EMBL) and the Pompeu Fabra University in Spain.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:


Story Source:

The above story is reprinted from materials provided by Institut de recherches cliniques de Montreal.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Journal Reference:

  1. R. Sheth, L. Marcon, M. F. Bastida, M. Junco, L. Quintana, R. Dahn, M. Kmita, J. Sharpe, M. A. Ros. Hox Genes Regulate Digit Patterning by Controlling the Wavelength of a Turing-Type Mechanism. Science, 2012; 338 (6113): 1476 DOI: 10.1126/science.1226804

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/health_medicine/genes/~3/bPgOwBOBkr8/121214112652.htm

hoya casa de mi padre corned beef and cabbage diners drive ins and dives jeff who lives at home 49ers news saint louis university

A tearful Obama: 'These children are our children' (CNN)

Share With Friends: Share on FacebookTweet ThisPost to Google-BuzzSend on GmailPost to Linked-InSubscribe to This Feed | Rss To Twitter | Politics - Top Stories Stories, RSS and RSS Feed via Feedzilla.

Source: http://news.feedzilla.com/en_us/stories/politics/top-stories/270822777?client_source=feed&format=rss

meryl streep martin scorsese sacha baron cohen best picture nominees 2012 academy awards 2012 albert nobbs a star is born

Friday, December 14, 2012

FAQ: 18 things you should know about prostate cancer | 89.3 KPCC

(Justin Sullivan/Getty Images)

Doctors review images of a prostate with cancer. Options other than radiation, chemotherapy or surgery exist - here are some questions to ask while considering the best approach to treatment.

This week, Governor Jerry Brown made headlines with the announcement that he is undergoing radiation treatment for ?localized? prostate cancer.?

The federal Centers for Disease Control and Prevention reports that prostate cancer is the most common cancer found in American men of all races.

Even so, there's a lot of confusion about biopsies and treatment options. So we spoke with Stuart Holden, M.D., director of Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center in Los Angeles and Mark S. Litwin, MD Chair of the Department of Urology at UCLA and compiled answers to these 18 Frequently Asked Questions about prostate cancer.

1. What is prostate cancer?

It?s a disease of? the prostate gland of the male reproductive system.

The American Cancer Society has an in-depth overview here.

2. What is the prostate gland and what function does it play?

The prostate is a walnut-sized gland that?s located inside a man?s body between his bladder and rectum. The prostate gland contains cells that make some of the seminal fluid that nourishes and carries sperm. The urethra ? the tube that carries urine - runs through the gland?s center. That's why changes in a man?s urinary or sexual function might indicate prostate cancer.

3. Does a diagnosis of prostate cancer mean an automatic death sentence?

Not at all. Most prostate cancer is slow growing, so those afflicted with it are often more likely to die from old age or from other causes of death than from prostate cancer.

4. How common is prostate cancer in the United States?

Very common. Nationwide, prostate cancer is the most common cancer among men of all races, according to the federal Centers for Disease Control and Prevention. (CDC)

It?s estimated that 30 percent of American men ages 50 and older - or about 10 million men - have prostate cancer, says Dr. Holden.

But most men with prostate cancer are unaware they have it. That's because the?vast majority of cases are "slow-growing pussy cats that men die?with, not?of,"?says Dr. Litwin.

5. How many U.S. men die each year of prostate cancer??

The disease ranks second to lung cancer as the leading cause of cancer deaths among men in the U.S., the CDC reports.

While that sounds ominous, the CDC puts the actual number of U.S. deaths from prostate cancer at about 28,000 a year. Drs. Holden and Litwin say when compared to the millions who are believed to be living with the disease, the death rate is proportionately very small.

?The risk of death from prostate cancer for the average Joe is extraordinarily low,? Dr. Litwin says.

6. What are some typical symptoms?

They include blood in a man?s urine or semen; problems with urinary function including weak urine flow; and difficulty with starting or holding back urination.

The cancer can also show symptoms through problems with sexual function that include difficulty getting an erection and painful ejaculation.

But for most men, prostate cancer is a silent disease. The most typical indicators include abnormal readings on PSA blood tests, which measure the protein produced by the prostate gland.

Another way doctors detect prostate cancer is by feeling a nodule or lump in the prostate during a digital rectal exam.

The?Prostate Cancer Foundation provides an overview of symptoms.

7. Does a high PSA blood test or lump on my prostate mean I have prostate cancer??

No. All it means is that there is a suspicion of prostate cancer. A biopsy is required before you can determine that cancer is present.

The CDC offers this information about PSA tests.

8. Should I get a biopsy if I have an abnormal PSA reading or a lump in my prostate?

That depends. Until recently, the automatic next step was for your doctor to order a biopsy. ?

These days, however, leaders in the field are opting to first consider a patient?s age and health before ordering a biopsy. If the patient is too elderly or too sick with other illnesses for a prostate diagnosis to add value to his life, it?s more likely his doctor will to forego a biopsy.

If you don't fall into those categories, a biopsy is the recommended next step.

9. What happens during a prostate cancer biopsy?

The doctor places an ultrasound probe into the rectum, which provides an image of the prostate. Local anesthesia is injected. Then a hollow-bore needle is inserted, usually through the rectum wall, into the prostate gland.?

Typically, about a dozen samples of tissue - about the size of a one-inch length of lead from a mechanical pencil - are taken from the prostate.

?Those samples go to the pathologist who studies them under a microscope and tells us if it?s cancer or a benign growth,? Dr. Litwin says.

10. Do biopsies pose any health risks?

They can. Among the risks is blood infection because the needle must pass through the rectum.

?The rectum is not the most sterile area of the body,? says Dr. Litwin. ?For that reason we always give people antibiotics around the time of the biopsy.?

But Drs. Litwin and Holden say the risk of blood infections is minimal.

11. What if my biopsy results in a cancer diagnosis? ?

Your doctor will next consider stage and grade of the tumor. ?

The stage of a prostate tumor?refers to whether it?s confined to the prostate or has spread to other sites in the body. The confined variety of prostate cancer, also known as? ?localized? or ?early-stage? prostate cancer, is the type that Governor Jerry Brown?s office has reported.

The grade or severity of the cancer is then measured on a 10-point scale that provides a ranking known as a ?Gleason?s score.? The higher the Gleason?s score, the more severe the cancer.

12. Do the stage and grade of a prostate tumor affect treatment decisions?

Yes. They have huge implications on decisions that a patient and doctor will make together regarding which treatment method is best.

13. What are the treatment options?

There are three main options: active surveillance, surgery, and radiation. ??

14. What is ?active surveillance? and what does it entail?

This treatment option involves the patient foregoing ? at least initially - surgery or radiation for ?active? surveillance of the tumor. This is a fairly new treatment approach recommended for those with slow-growing tumors as a way to avoid surgery and radiation.

Dr. Holden says those who opt for ?active surveillance? will undergo regular PSA blood tests, digital rectal exams and repeated biopsies.

Those diagnosed with prostate cancer can now sign onto the world's first online medical data base for men with the disease.?The interactive data base allows them to track progression of the disease before seeking aggressive treatments.

15. What does prostate cancer surgery involve?

Today, prostate surgery typically involves removal of the entire prostate gland. But new imaging methods under study at UCLA?might change that.

The new technology combines ultrasound and MRI imaging that researchers say may allow doctors to see, then target suspicious growths on a patient?s prostate gland for more accurate biopsies. By contrast, in prostate biopsies doctors can?t see the tumor.

The American Cancer Society offers more information.

16. What does radiation treatment involve?

Dr. Holden says doctors often recommend external beam radiation for early-stage, localized prostate cancer. The treatments usually last between six to seven weeks, which each treatment session lasting about five minutes.

?Basically, it?s completely external and like having your picture taken,? says Dr. Holden.

Advances in radiation treatment, which allows for focused beams to target the just the prostate, reduce the risks and have made it more effective.

The American Cancer Society offers more about radiation treatment for prostate cancer.

17. What are the potential side effects of surgery or radiation treatment?

Surgery and radiation pose serious side effects, most notably incontinence and impotence. An individual?s likelihood of suffering either or both depends on age, health and existing sexual functionality before surgery.

Dr. Holden says the incidence of sexual dysfunction is about equal with both treatments.?? ?Roughly 50 percent of men with either treatment retain sexual function, assuming they had good sexual function to begin with,? he says.

Surgery, by contrast, initially poses more urinary tract problems than radiation, he says.?? ?However, some of the men develop more urinary dysfunction eight or 10 years after radiation treatment,?Dr. Holden says. ?So over the long run, radiation catches up.?

18. What?s new in prostate cancer research?

The Prostate Cancer Foundation offers?a list of advances in prostate cancer research.

Source: http://www.scpr.org/news/2012/12/14/35248/18-things-you-need-know-about-prostate-cancer/

chris brown and rihanna nightline brady quinn brady quinn bloom box fat tuesday obama sweet home chicago